Clinical trials
Recurrent Acute Lymphoblastic Leukemia clinical trials
Below are recruiting recurrent acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 75 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT06287528RecruitingPhase 1
CAR T‑cell therapy with IL‑18 for returning B‑cell leukemia
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
Basking Ridge, New JerseyAges 17 years+ - NCT06144606RecruitingPhase 2
KTE-X19 CAR T for MRD+ B-ALL
This trial tests a CAR T-cell therapy called KTE-X19 for people with B-cell ALL that is in remission but still has trace disease (MRD-positive). The goal is to see if this treatment can eliminate the remaining cancer cells and prevent relapse.
Tampa, FloridaAges 18 years+ - NCT04260022RecruitingPhase 1
Drug study for hard-to-treat CML or Ph+ ALL
This Phase 1 study tests HQP1351 for people with CML or Ph+ ALL that has not responded well to standard targeted pills (TKIs), or those who could not tolerate them. It’s designed to see whether the treatment can work and how safe it is for this difficult-to-treat group.
Birmingham, AlabamaAges 18 years+ - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT05884333RecruitingPhase 2
Cord blood transplant for adults with blood cancer
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
New York, New YorkAges 21–65 - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT05800210RecruitingPhase 2
T cell and B cell immune “wipeout” after stem cell transplant
This Phase 2 trial studies whether removing certain immune cells (alpha/beta T cells and CD19+ B cells) around the time of a stem cell transplant can improve outcomes for people with high-risk blood cancers. It may help by reducing the immune responses that can interfere with the transplant working, while keeping the process safe.
Gainesville, FloridaAges 6 months–39 years - NCT05581030RecruitingPhase 1
Newly diagnosed ALL: testing a treatment after Hyper-CVAD
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
Tampa, FloridaAges 18–50 - NCT05495035RecruitingPhase 1
Olverembatinib plus APG-2575 for children with resistant leukemia
This study tests a new combination of two oral drugs (olverembatinib and APG-2575) for children with a type of leukemia (Ph+ ALL) that has returned or stopped responding to standard treatments. The goal is to see if this combination is safe and effective.
Hefei, AnhuiAges 1–18 - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05334823RecruitingPhase 2
CAR T-cell treatment for CD19-positive relapsed leukemia in children
This Phase 2 trial tests pCAR-19B, a customized immune-cell treatment for children and teens with CD19-positive B-ALL that has come back or did not respond to standard therapy. If eligible, you would receive the cell infusion after cell collection and testing to make sure the leukemia cells have the right marker.
Beijing, Beijing MunicipalityAges 3–21 - NCT04836507RecruitingPhase 1/Phase 2
Study of a lab-made cell therapy for lymphoma and leukemia
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Birmingham, AlabamaAges 1–30 - NCT03934372RecruitingPhase 1/Phase 2
Ponatinib for children with relapsed or hard-to-treat cancers
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
GhentAges 1–17 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Birmingham, AlabamaAges 18 years+ - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years
Hear when a new Recurrent Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 75 recruiting recurrent acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent B Acute Lymphoblastic Leukemia
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Acute Lymphoblastic Leukemia
- B-cell Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, in Relapse
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.